SG11202012619WA - Methods for improving response to anti-lif antibody treatment in individuals with cancer - Google Patents

Methods for improving response to anti-lif antibody treatment in individuals with cancer

Info

Publication number
SG11202012619WA
SG11202012619WA SG11202012619WA SG11202012619WA SG11202012619WA SG 11202012619W A SG11202012619W A SG 11202012619WA SG 11202012619W A SG11202012619W A SG 11202012619WA SG 11202012619W A SG11202012619W A SG 11202012619WA SG 11202012619W A SG11202012619W A SG 11202012619WA
Authority
SG
Singapore
Prior art keywords
individuals
cancer
methods
antibody treatment
improving response
Prior art date
Application number
SG11202012619WA
Other languages
English (en)
Inventor
Suarez Joan Seoane
Folgueira Judit Anido
Robin Hallett
Peter Bayliss
Ajitha Jeganathan
Patricia Giblin
Ruano Isabel Huber
Jeanne Magram
Garcia Monica Pascual
Teixidor Ester Bonfill
Rigol Ester Planas
Original Assignee
Medimmune Ltd
Fundacio Privada Institut D Investig Oncologica De Vall Hebron
Fundacio Privada Inst Catalana De Recerca I Estudis Avancats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Fundacio Privada Institut D Investig Oncologica De Vall Hebron, Fundacio Privada Inst Catalana De Recerca I Estudis Avancats filed Critical Medimmune Ltd
Publication of SG11202012619WA publication Critical patent/SG11202012619WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202012619WA 2018-06-18 2019-06-17 Methods for improving response to anti-lif antibody treatment in individuals with cancer SG11202012619WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382431 2018-06-18
EP19382131 2019-02-22
PCT/IB2019/000806 WO2019243898A2 (en) 2018-06-18 2019-06-17 Methods for improving response to anti-lif antibody treatment in individuals with cancer

Publications (1)

Publication Number Publication Date
SG11202012619WA true SG11202012619WA (en) 2021-01-28

Family

ID=68136437

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012619WA SG11202012619WA (en) 2018-06-18 2019-06-17 Methods for improving response to anti-lif antibody treatment in individuals with cancer

Country Status (11)

Country Link
US (1) US20210253691A1 (zh)
EP (1) EP3807315A2 (zh)
JP (1) JP2021529162A (zh)
KR (1) KR20210024007A (zh)
CN (1) CN112703202A (zh)
AU (1) AU2019291305B2 (zh)
CA (1) CA3103763A1 (zh)
IL (1) IL279484A (zh)
MA (1) MA52299A (zh)
SG (1) SG11202012619WA (zh)
WO (1) WO2019243898A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019012691A2 (pt) * 2016-12-19 2019-11-19 Fundacio Privada Inst Catalana De Recerca I Estudis Avancats anticorpos contra a lif e seus usos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
WO2018022666A1 (en) * 2016-07-26 2018-02-01 Flagship Pioneering, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Also Published As

Publication number Publication date
KR20210024007A (ko) 2021-03-04
MA52299A (fr) 2021-04-21
IL279484A (en) 2021-01-31
JP2021529162A (ja) 2021-10-28
AU2019291305A1 (en) 2021-01-28
EP3807315A2 (en) 2021-04-21
AU2019291305B2 (en) 2024-03-21
CA3103763A1 (en) 2019-12-26
WO2019243898A8 (en) 2020-09-24
WO2019243898A3 (en) 2020-02-13
CN112703202A (zh) 2021-04-23
WO2019243898A2 (en) 2019-12-26
US20210253691A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
IL265309B2 (en) Bispecific antibodies against MUC16 and antibodies against MUC16 for use in cancer treatment
HK1243005A1 (zh) 抗lilrb抗體及其在檢測和治療癌症中的用途
IL256687B (en) Isolated tau-binding antibody and its use in treatment and diagnosis
NZ739750A (en) Anti-tigit antibodies and methods of use
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
FI3500299T3 (fi) Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
IL271221A (en) Antibodies that bind il-1beta for use in cancer therapy
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
SG11201507563SA (en) Cancer treatment using antibodies that bind cell surface grp78
IL248511A0 (en) Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
IL267567B1 (en) Anti-CD3 antibody - for use in treating or preventing cancer and molecules containing the antibody
IL258980A (en) Preparation of bispecific antigens and their use in cancer
EP3303402A4 (en) ANTIBODIES TO GLYPICAN-3 AND ITS USE TO CANCER DIAGNOSIS AND TREATMENT
SG10202112636SA (en) Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
ZA202000851B (en) Antibodies useful in cancer diagnosis
WO2015153997A3 (en) Notch3 antibodies and uses thereof
IL280830A (en) Bracelets for use in cancer treatment methods
SG11202000634UA (en) Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
ZA202204422B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
IL255314A0 (en) Anti-ap2 antibodies and antigen-binding agents for the treatment of metabolic disorders
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
PT3144676T (pt) Kit compreendendo anticorpo que se liga especificamente à proteína de fator b do complemento e anticorpo que se liga especificamente à proteína do antigénio carboidrato 19-9 para diagnosticar o cancro pancreático
EP3240566A4 (en) Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
IL279484A (en) Methods for improving response to anti-LIF antibody therapy in individuals with cancer